Glob­al Blood Ther­a­peu­tics buoyed by good news from FDA; Cigna to help cov­er pricey ther­a­pies

→ Glob­al Blood Ther­a­peu­tics $GBT has much to cheer about. Not on­ly has the FDA grant­ed its sick­le cell dis­ease (SCD) drug pri­or­i­ty re­view, the agency is not hold­ing an ad­vi­so­ry com­mit­tee to de­lib­er­ate on the drug. Shares of the San Fran­cis­co-based biotech jumped more than 14% to $54.25 be­fore the bell on Thurs­day. The US reg­u­la­tor is ex­pect­ed to de­cide on the once-dai­ly pill vox­elo­tor — which is de­signed to work by in­creas­ing he­mo­glo­bin’s affin­i­ty for oxy­gen — by Feb­ru­ary 26, 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER